Regarding in situ component in IDC + DCIS lesions, concordance rates were 86.4% for ER status, 93.2% for PR status, 98.2% for HER2 status, and 76.3% for Ki-67 result, respectively (Fig. 2B). This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.